MedMen Enterprises (MMNFF) P/S Ratio
MedMen Enterprises (MMNFF) has a price-to-sales ratio of 3.08x, placing it in the Fair range for cannabis stocks. The company has a market cap of $1.50B and TTM revenue of $1.76B. Revenue is declining 18.9% YoY.
P/S Ratio (TTM)
3.08x
EV/Revenue
7.05x
Market Cap
$1.50B
Revenue Growth
-18.9%
Valuation Breakdown
| Metric | Value |
|---|---|
| Stock Price | $63.86 |
| Market Capitalization | $1.50B |
| TTM Revenue | $1.76B |
| Price-to-Sales (TTM) | 3.08x |
| EV/Revenue | 7.05x |
| Revenue Growth (YoY) | -18.9% |
| Gross Margin | -6.8% |
| Sector | MSO |
| Exchange | OTC |
| Valuation Range | Fair |
Frequently Asked Questions
What is MMNFF's current price-to-sales ratio?+
The price-to-sales (P/S) ratio divides MedMen Enterprises's market capitalization by its trailing twelve months of revenue. Since many cannabis companies are not yet profitable, P/S is one of the most widely used valuation metrics in the sector. A lower ratio may suggest the stock is undervalued relative to revenue.
How does MMNFF's P/S compare to other cannabis stocks?+
P/S ratios in cannabis typically range from 0.5x to 5x depending on growth rate, profitability, and market sentiment. High-growth companies command higher multiples, while mature, lower-growth companies trade at lower multiples. Compare MedMen Enterprises to peers in the same sub-sector (MSO, LP, ancillary) for meaningful context.
Is MMNFF overvalued or undervalued based on P/S?+
A single metric like P/S cannot definitively determine if MedMen Enterprises is over- or undervalued. Consider P/S alongside revenue growth rate, gross margins, cash position, and competitive dynamics. A company growing revenue at 50% YoY may justify a higher P/S than one growing at 5%. Also consider enterprise value-to-revenue (EV/Revenue) which accounts for debt and cash.